Cybin Inc. Common Stock
HELP
Rang in aandelen
#11559
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Aandeelprijs
$10.30
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$638.32M
Verandering (1 dag)
2.88%
Verandering (1 jaar)
9,119.52%
Land
CA
Handel Cybin Inc. Common Stock (HELP)
Categorie
Healthcare
Koersgeschiedenis voor Cybin Inc. Common Stock (HELP)
Hoogste slotkoers: $0.12 op 2023-10-01
Laagste slotkoers: $0.40 op 2021-06-01
Laagste slotkoers: $0.40 op 2021-06-01
Koersgeschiedenis van Cybin Inc. Common Stock van 2021 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2023 | 81.70% |
| 2022 | -76.32% |
| 2021 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
